The caveats: It is difficult to study. The strongest evidence is for palliative care in hospitals.
The caveat: The prices are now falling for various reasons, but the high cost still means many who might benefit don’t have access to the medications.
The caveats: Recent research says the evidence for improved outcomes was of moderate quality. And VBID still hasn’t proved its mettle as a cost saver.